Palantir CTO Says Some AI Researchers Are So Sure It Will Cure Cancer They’ve Started 'Smoking' — Warns Both AI Extremes Reflect ‘Social Delusion’

Shares of semiconductor and chip companies are trading lower as rising inflation concerns and elevated energy prices fuel expectations for further Fed rate hikes. Elevated borrowing costs could pressure semiconductor manufacturing and AI infrastructure investments while straining customer budgets. The Philadelphia Semiconductor Index (SOX) has declined for seven consecutive trading sessions, matching its longest losing streak since the 2008 financial crisis.

What's Going On With Arm Stock Friday?

Arm Holdings (ARM) stock loses momentum as investors weigh a legal setback, lofty valuation and profit-taking after a massive rally.

Not AMD. Not Broadcom. This is the Chip Designer Nvidia Investors Should Be Watching

Arm Holdings is a critical chip designer that Nvidia investors should monitor closely. Unlike AMD and Broadcom, Arm doesn't compete with Nvidia but rather supplies the architecture that powers Nvidia's Vera CPUs. Arm's licensing model generates predictable revenue streams, with royalties comprising 55% of Q1 FY2027 revenue of $1.3 billion. The company has captured over 50% of the hyperscaler market and continues strong growth, though its valuation at 150x forward earnings is steep compared to peers.

Arm vs. Credo Technology Group: Which Semiconductor Stock Is a Better Buy in 2026?

The article compares two semiconductor companies: Arm, which licenses chip architecture used in billions of devices globally with strong profitability and low risk, and Credo Technology Group, which provides high-speed interconnects for AI data centers with explosive 205% revenue growth but higher customer concentration risk. The author recommends Credo for its superior growth trajectory despite Arm's defensible business model.

Novo Nordisk and Eli Lilly Just Got Some Fantastic News

A NIH-funded study found that the GLP-1 drug semaglutide extended lifespan and slowed aging in older mice by improving muscle and cognitive function and reducing inflammation. The findings could accelerate adoption of GLP-1 drugs from Novo Nordisk and Eli Lilly, with forecasts predicting 25 million Americans on these treatments by 2030 and a market reaching $190 billion by 2035.

9 Of 11 Sectors Rise In Friday Trading As Cyclicals Lead

Nine of 11 sectors are higher in Friday’s regular session, with cyclical sectors holding the top three positions. The leaders are separated rather than clustered, with no single gap clearly standing apart from the other breaks across the table.